Development · 3 Nov 2026
MANKIND, full dossier1 publisher has reported this development. Each act of reporting is below, cited.
Mankind Pharma posted 17 per cent Y-o-Y sales growth in Q2FY27, while Ebitda grew faster at 27 per cent Y-o-Y, resulting in 210 bps Y-o-Y margin expansion to 27 per cent.
A single act of reporting so far, corroborating sources join this record as they publish.
Bank of India is quoting at Rs 154.3, up 1.91% on the day as on 12:39 IST on the NSE.
14 Nov 2026 · 1 publisher
Mankind Pharma reported revenue of Rs 14,278 crore in FY26.
11 Nov 2026 · 1 publisher
9 Nov 2026 · 1 publisher
Mankind Pharma announced the transcript of the Earnings Conference Call for Q2 & H1 FY27.
1 Nov 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.